Cambridge Investment Research Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Cambridge Investment Research Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-996	Closed	-$8K	–	3321
2023 Q1	$8K	Sell	996 -4	-0.4%	-$53	﹤0.01%	3137
2022 Q4	$12K	Buy	1,000 +81	+9%	+$926	﹤0.01%	3073
2022 Q3	$13K	Hold	919	–	–	﹤0.01%	3017
2022 Q2	$32K	Hold	919	–	–	﹤0.01%	2974
2022 Q1	$37K	Sell	919 -7	-0.8%	-$300	﹤0.01%	3097
2021 Q4	$39K	Hold	926	–	–	﹤0.01%	3114
2021 Q3	$63K	Hold	926	–	–	﹤0.01%	3010
2021 Q2	$71K	Buy	926 +85	+10%	+$5.18K	﹤0.01%	3002
2021 Q1	$55K	Buy	841 +143	+20%	+$11.1K	﹤0.01%	2803
2020 Q4	$24K	Buy	698 +29	+4%	+$1.29K	﹤0.01%	2677
2020 Q3	$37K	Buy	+669	New	+$39.7K	﹤0.01%	2466
2019 Q1	–	Sell	-229	Closed	-$36K	–	2359
2018 Q4	$36K	Buy	+229	New	+$43.9K	﹤0.01%	2105

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Cambridge Investment Research Advisors's DMK Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 996 shares — an estimated $8K sold.

Cambridge Investment Research Advisors first reported a position in DMK in Q4 2018 and held it in 12 quarters. The position peaked at $71K in Q2 2021. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Cambridge Investment Research Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Cambridge Investment Research Advisors sold 996 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $8K.
Cambridge Investment Research Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2018 and held it in 12 quarters.
Cambridge Investment Research Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $71K in Q2 2021.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.